In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Colon and Rectal Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Combining Targeted Therapies for Metastatic Colorectal Cancer
    (Posted: 08/15/2006, Updated: 02/06/2007) - In this trial, researchers are combining the targeted monoclonal antibody cetuximab (Erbitux) with another targeted drug called sorafenib (Nexavar) to treat patients with metastatic colorectal cancer whose tumors show epidermal growth factor receptor (EGFR) activity.
  • Gene Therapy for Metastatic Cancer
    (Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.
  • Treatment Based on Colorectal Tumor Protein Level
    (Posted: 11/14/2006) - In this clinical trial, researchers will measure the level of a protein called thymidylate synthase (TS) in the tumors of patients with metastatic colorectal cancer and assign patients to one of two treatment groups based on their TS levels.
  • Monoclonal Antibodies for Metastatic Colorectal Cancer
    (Posted: 09/19/2006) - In this trial, patients will receive one of two targeted agents, or a combination of the two, that were recently approved by the U.S. Food and Drug Administration for use with combination chemotherapy in the treatment of metastatic colorectal cancer.
  • Adjuvant Treatment of Rectal Cancer
    (Posted: 05/16/2006) - In this trial, patients who were treated previously with neoadjuvant chemoradiotherapy (chemotherapy combined with radiation therapy) will be randomly assigned to receive adjuvant chemotherapy with or without the addition of the monoclonal antibody bevacizumab, which inhibits tumor blood vessel formation. Researchers will compare the overall survival of patients in the two treatment groups.
< Previous  1 2 3 4 5  Next >